Pancreatic Cancer Research

ResearcherUniversity of TorontoNo recent work listed

Wei Fang Dai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1416-1070; OpenAlex author ID A5101571343. Sources: OpenAlex.

Their work

Papers
5
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 5

  1. Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based … Co-author DOI 10.1016/j.clon.2023.02.008↗
  2. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkac047↗
  3. The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2021.33388↗
  4. Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer? Co-author DOI 10.1002/cam4.2704↗
  5. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Co-author DOI 10.1002/cam4.2705↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kelvin Chan · 5 shared papers, 2020–2023 · strength 0.61
  2. Michael Jonathon Raphael · 3 shared papers, 2021–2023 · strength 0.42
  3. James Biagi · 2 shared papers, 2020–2023 · strength 0.26
  4. Natalie G. Coburn · 2 shared papers, 2020–2023 · strength 0.26
  5. Nicole Mittmann · 2 shared papers, 2020–2022 · strength 0.22
  6. Vanessa Sarah Arciero · 1 shared paper, 2022 · strength 0.13
  7. Ambica Parmar · 1 shared paper, 2022 · strength 0.13
  8. Erin Diane Kennedy · 1 shared paper, 2020 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.